A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum.
J Antimicrob Chemother
; 76(7): 1865-1873, 2021 06 18.
Article
in English
| MEDLINE | ID: covidwho-1189464
ABSTRACT
BACKGROUND:
As global confirmed cases and deaths from coronavirus disease 2019 (COVID-19) surpass 100 and 2.2 million, respectively, quantifying the effects of the widespread treatment of remdesivir (GS-5734, Veklury) and the steroid dexamethasone is becoming increasingly important. Limited pharmacokinetic studies indicate that remdesivir concentrations in serum decrease quickly after dosing, so its primary serum metabolite GS-441524 may have more analytical utility.OBJECTIVES:
We developed and validated a method to quantify remdesivir, its metabolite GS-441524 and dexamethasone in human serum.METHODS:
We used LC-MS/MS and applied the method to 23 serum samples from seven patients with severe COVID-19.RESULTS:
The method has limits of detection of 0.0375 ng/mL for remdesivir, 0.375 ng/mL for GS-441524 and 3.75 ng/mL for dexamethasone. We found low intra-patient variability, but significant inter-patient variability, in remdesivir, GS-441524 and dexamethasone levels.CONCLUSIONS:
The significant inter-patient variability highlights the importance of therapeutic drug monitoring of COVID-19 patients and possible dose adjustment to achieve efficacy.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Tandem Mass Spectrometry
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Antimicrob Chemother
Year:
2021
Document Type:
Article
Affiliation country:
Jac
Similar
MEDLINE
...
LILACS
LIS